Open AccessAn overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines
Author(s) -
Khoshnood Saeed,
Arshadi Maniya,
Akrami Sousan,
Koupaei Maryam,
Ghahramanpour Hossein,
Shariati Aref,
Sadeghifard Nourkhoda,
Heidary Mohsen
Publication year - 2022
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.24418
Subject(s) - pandemic , virology , inactivated vaccine , attenuated vaccine , medicine , covid-19 , population , clinical trial , immune system , vaccination , immunology , disease , biology , environmental health , infectious disease (medical specialty) , virulence , gene , pathology , biochemistry
After about 2 years since severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), first infections were detected in Wuhan city of China in December 2019, which was followed by a worldwide pandemic with a record of 5.41 million deaths. Due to urgent need for the development of a safe and effective vaccine for coronavirus disease 2019 (COVID‐19), attempts for producing efficient vaccines are inexhaustibly continuing. According to a report by the World Health Organization (WHO) on COVID‐19 vaccine tracker and landscape, there are 149 vaccine candidates all over the world. Inactivated SARS‐CoV‐2 vaccines as a conventional vaccine platform consist of whole virus particles grown in cell culture and inactivated by chemicals. Because of benefits such as antigenic similarity to real virion inducing humoral and cellular immune responses and ease for transport and storage, these vaccines, including the vaccines produced by Bharat Biotech, Sinopharm, and Sinovac, are in use at large scales. In this study, we have a review on inactivated SARS‐CoV‐2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features.